Resolutions of the Annual General Meeting of Evotec
Advertisement
Shareholders of Evotec AG approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting.
The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented the Company's performance for the year 2012 and provided the shareholders with an update on the topic innovation efficiency within Action Plan 2016.
Furthermore, the Annual General Meeting elected Dr Claus Braestrup as new member of the Supervisory Board. Dr Braestrup has extensive experience in executive-level functions at international pharmaceutical companies - among others as former President and CEO and Head of Research and Development of Lundbeck A/S and as Vice President for pharmaceutical research at Novo Nordisk A/S.
Dr Braestrup succeeds Dr Flemming Ørnskov until the completion of the Annual General Meeting 2014. Dr Ørnskov resigned as member and Chairman of the Supervisory Board upon conclusion of the Annual General Meeting 2013. In a subsequent meeting of the Supervisory Board, Dr Walter Wenninger, former Deputy Chairman of the Supervisory Board, was elected as Chairman of the Supervisory Board and Mr Roland Oetker was elected as his Deputy Chairman.
The Annual General Meeting also approved the proposal of the Management Board and the Supervisory Board to change the remuneration of the Supervisory Board to a fixed remuneration in form of cash compensation from fiscal year 2013 onwards. Moreover, the Annual General Meeting passed all of the other agenda items requiring shareholders' approval, thereunder the resolution on single amendments of the articles of association and the appointment of KPMG as the auditor for fiscal year 2013.